Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer

This study is currently recruiting participants.
Verified January 2014 by M.D. Anderson Cancer Center
Sponsor:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01596140
First received: May 8, 2012
Last updated: January 28, 2014
Last verified: January 2014
  Purpose

The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with either everolimus or temsirolimus. The safety of these drug combinations will also be studied.

Vemurafenib is designed to block BRAF inside the cancer cells, which is a mutation that is involved in cancer cell growth.

Temsirolimus and everolimus are designed to block the growth of cancer cells, which may cause cancer cells to die.


Condition Intervention Phase
Advanced Cancer
Solid Tumor
Drug: Vemurafenib
Drug: Everolimus
Drug: Temsirolimus
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf®) in Combination With an mTOR Inhibitor, Everolimus (Afinitor®) or Temsirolimus (Torisel®), in Subjects With Advanced Cancer

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Maximum Tolerated Dose (MTD) of combination Vemurafenib [ Time Frame: First cycle of 28 day cycle ] [ Designated as safety issue: Yes ]
    The MTD of combination Vemurafenib and Everolimus or Vemurafenib and Temsirolimus is defined as the highest dose studied in which the incidence of dose limiting toxicity (DLT) was less than one third (33%) of the participants at that dose level.


Estimated Enrollment: 114
Study Start Date: December 2012
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vemurafenib + Oral Everolimus
Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Oral Everolimus starting dose 5 mg daily.
Drug: Vemurafenib
Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.
Other Names:
  • Zelboraf®
  • PLX4032
  • RO5185426
Drug: Everolimus
Starting dose 5.0 mg by mouth daily for 28-day study cycle.
Other Names:
  • Afinitor®
  • RAD001
Experimental: Vemurafenib + Intravenous Temsirolimus
Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Intravenous Temsirolimus starting dose 15 mg daily on Days 1, 8, 15, and 22 of each cycle.
Drug: Vemurafenib
Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.
Other Names:
  • Zelboraf®
  • PLX4032
  • RO5185426
Drug: Temsirolimus
Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.
Other Name: Temodar

  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Confirmation of BRAF mutation-positive malignancy is required for selection of patients for vemurafenib therapy
  2. Measurable or non-measurable disease by RECIST 1.1.
  3. Patients with advanced cancer should be refractory to standard therapy, relapsed after standard therapy, or have no standard therapy available that improves survival by at least three months.
  4. Patients must be at least 3 weeks past receiving cytotoxic therapy and at least 5 half-lives after their previous treatment or 3 weeks, whichever is shorter, after biologic therapy. Patients may receive palliative radiotherapy immediately or during treatment provided that not all target lesions are radiated.
  5. ECOG performance status </= 2 (Karnofsky >/= 60%; Lansky Score >/= 50).
  6. Patients must have normal organ and marrow function defined as: absolute neutrophil count >/=1,000/mL; platelets >/=50,000/mL; creatinine < 2.0; total bilirubin < 2.0; ALT(SGPT) </= 3 X ULN; Exception for patients with liver metastasis: ALT(SGPT) </= 5 X ULN.
  7. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days after the last dose.
  8. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Patients with uncontrolled concurrent illness, including but not limited to: ongoing or active infection requiring hospitalization; psychiatric illness/social situations that would limit compliance with study requirements.
  2. Exclusion of patients with creatinine >2.0 and bilirubin > 2.0.
  3. Pregnant or lactating women.
  4. Patients with a history of bone marrow transplant within the previous two years.
  5. Patients with a known hypersensitivity to any of the components of the drug products.
  6. Patients with major surgery within 30 days prior to entering the study.
  7. Patients with a baseline QTc > 500 ms.
  8. Patients who are unable to swallow pills.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01596140

Contacts
Contact: Vivek Subbiah, MD 713-794-1226

Locations
United States, Texas
UT MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Principal Investigator: Vivek Subbiah, MD UT MD Anderson Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT01596140     History of Changes
Other Study ID Numbers: 2012-0153
Study First Received: May 8, 2012
Last Updated: January 28, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Vemurafenib
Everolimus
Afinitor
RAD001
temsirolimus
BRAF gene mutation
solid tumor
relapsed BRAF mutation positive malignant melanoma
refractory BRAF mutation positive malignant melanoma

Additional relevant MeSH terms:
Neoplasms
Everolimus
Sirolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Antifungal Agents
Anti-Infective Agents
Anti-Bacterial Agents

ClinicalTrials.gov processed this record on April 14, 2014